Abstract
Objective The aim of this study was to assess the consumption of anti-haemophilic drugs by adults and children with severe haemophilia A or B (residual activity of FVIII or FIX ≤2%) and to quantify the average direct medical costs. Method A retrospective multicentre cost-of-illness study from the perspective of French national health insurance system. The costs include only the use of clotting factors. Main outcome measure Consumption was expressed in UI/kg/year and costs in euros/kg/year. Results From January 1, 2001 to December 31, 2002, data from 81 adults and 30 children with severe haemophilia A (n = 92) or B (n = 19) and included in the “SNH” were collected and analysed. A coagulation factor inhibitor was present in 10 patients (9%). Four of them were high responders. Mean age and body weight were respectively 28 ± 17 years and 58 ± 24 kg. Except for one adult patient, all (99%) had outpatient treatment, 44 patients (40%) were hospitalized and treated by recombinant or/and plasma-derived FVIII or FIX or/and rFVIIa. Overall median annual consumption of anti-haemophilic drugs per patient was estimated at 1,333 UI/kg, with a median cost-of-illness of 1,156 euros/kg. Patients with severe haemophilia B consumed more than patients with severe haemophilia A, though not significantly (P = 0.096), with a median of 2,167 vs. 1,100 UI/kg/year and a median cost of 1,760 vs. 917 euros/kg/year (P = 0.13). Children consumed respectively more than adults (P = 0.008), with a median of 3,204 vs. 1,106 UI/kg/year and a median cost of 2,614 vs. 913 euros/kg/year (P = 0.012). The median cost for patients with an inhibitor was 3,291 euros/kg/year, approximately threefold higher than that of patients without an inhibitor (926 euros/kg/year) (P = 0.022). Conclusion It suggests a higher consumption and cost of anti-haemophilic drugs among children when compared to adults. Haemophilia B patients did not consume significantly more than haemophilia A patients, whereas the consumption and cost for patients with or without inhibitors differed significantly.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Macik BG. Treatment of factor VIII inhibitors: products and strategies. Semin Thromb Haemost 1993;19(1):13–24
DiMichele DM. Inhibitors in haemophilia: a primer. Haemophilia 2000; 6(1):38–40
Sultan Y. The French Hemophilia Study Group. Prevalence of inhibitors in a population of 3,435 hemophilia patients in France. Thromb Haemost 1992;67:600–2
Molho P, Rolland N, Lebrun T, Dirat G, Courpied JP, Croughs T, et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. Haemophilia 2000;6(1):23–32
Jasso-mosqueda JG, Omnès LF, Gomez E, et al. Description of the management of patients suffering from type A haemophilia [Description de la prise en charge de l’hémophilie sévère de type A par le programme de médicalisation des Systèmes d’information : intérêts et limites]. J Econ Med 2000;18:323–30
D’Alche-Gautier MJ, Gautier P, Stieltjes N, et al. Economic study of clotting factor therapy in haemophilia [Coût du traitement substitutif des hémophiles hospitalisés]. J Econ Med 2001;19:157–66
Schramm W, Royal S, Kroner B, Berntorp E, Giangrande P, Ludlam C, et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002;8(1):33–43
Auerswald G, Von Depka Prondzinski M, Ehlken B, Kreuz W, Kurnik K, Lenk H, et al. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany. Haemophilia 2004;10:499–508
Chang H, Sher GG, Blanchette VS, Teitel JM. The impact on the cost of clotting factor replacement therapy in haemophilia A in Canada. Haemophilia 1999;5(4):247–52
Rivard GE, Vick S. Factor VIII inhibitor treatment. Economics of inhibitor treatment in Canada. Semin Hematol 1994;31(4):41–3
Bohn RL, Aledort LM, Putnam KG, Ewenstein BM, Mogun H, Avorn J. The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia 2004;10(1):63–8
Gautier P, D’Alche-Gautier MJ, Coatmelec B, Marques-Verdier A, Bertrand MA, Dieval J, et al. Cost related to replacement therapy during hospitalization in haemophiliacs with or without inhibitors: experience of six French haemophilia centres. Haemophilia 2002;8(5):674–9
Goudemand J. Hemophilia. Treatment of patients with inhibitors: cost issues. Haemophilia 1999;5(6):397–401
Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992;339:594–8
Calvez T, Biou M, Costagliola, Jullien AM, Laurian Y, Rossi F, et al. The French haemophilia cohort: rationale and organization of a long-term national pharmacosurveillance system. Haemophilia 2001;7:82–8
Gill FM. The natural history of factor VIII inhibitors in patients with haemophilia A. Prog Clin Biol Res 1984;150:19–29
Shapiro A. Inhibitor treatment: state of the art. Semin Hematol 2001;38:26–34
Acknowledgements
We are indebted to Bayer Laboratory and Biotech Division for logistic and organisational assistance. We also thank Ms Pamela Albert for English assistance in the correction of the manuscript.
Conflicts of interest
There is no potential conflict of interest related to the content of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nerich, V., Tissot, E., Faradji, A. et al. Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres. Pharm World Sci 30, 287–292 (2008). https://doi.org/10.1007/s11096-007-9181-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-007-9181-4